JP2019527231A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527231A5
JP2019527231A5 JP2019504928A JP2019504928A JP2019527231A5 JP 2019527231 A5 JP2019527231 A5 JP 2019527231A5 JP 2019504928 A JP2019504928 A JP 2019504928A JP 2019504928 A JP2019504928 A JP 2019504928A JP 2019527231 A5 JP2019527231 A5 JP 2019527231A5
Authority
JP
Japan
Prior art keywords
cancer
combination
subject
sarcoma
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019504928A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527231A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/044513 external-priority patent/WO2018026663A1/en
Publication of JP2019527231A publication Critical patent/JP2019527231A/ja
Publication of JP2019527231A5 publication Critical patent/JP2019527231A5/ja
Pending legal-status Critical Current

Links

JP2019504928A 2016-08-01 2017-07-28 がんを治療するための組み合わせ Pending JP2019527231A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662369639P 2016-08-01 2016-08-01
US62/369,639 2016-08-01
PCT/US2017/044513 WO2018026663A1 (en) 2016-08-01 2017-07-28 Combinations for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2019527231A JP2019527231A (ja) 2019-09-26
JP2019527231A5 true JP2019527231A5 (https=) 2020-09-10

Family

ID=61073280

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019504928A Pending JP2019527231A (ja) 2016-08-01 2017-07-28 がんを治療するための組み合わせ

Country Status (5)

Country Link
US (1) US20190185567A1 (https=)
EP (1) EP3490561A4 (https=)
JP (1) JP2019527231A (https=)
CN (1) CN109689056A (https=)
WO (1) WO2018026663A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019533022A (ja) 2016-10-24 2019-11-14 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
US11247990B1 (en) 2017-12-07 2022-02-15 Array Biopharma Inc Bicyclic fused pyridine compounds as inhibitors of TAM kinases
WO2019183587A1 (en) 2018-03-23 2019-09-26 Yumanity Therapeutics, Inc. Compounds and uses thereof
UY38349A (es) 2018-08-30 2020-03-31 Array Biopharma Inc Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met
WO2020154571A1 (en) 2019-01-24 2020-07-30 Yumanity Therapeutics, Inc. Compounds and uses thereof
WO2020198026A1 (en) * 2019-03-22 2020-10-01 Yumanity Therapeutics, Inc. Compounds and uses thereof
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
US11419844B2 (en) 2019-11-19 2022-08-23 Provectus Pharmatech, Inc. Halogenated xanthene composition and method for treating hematologic cancers
MX2022005828A (es) * 2019-11-19 2022-07-04 Provectus Pharmatech Inc Composicion y metodo para tratamiento de canceres hematologicos.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1212422B1 (en) * 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
PT2769737T (pt) * 2009-07-20 2017-06-29 Bristol Myers Squibb Co Combinação de um anticorpo anti-ctla4 com etopósido para o tratamento sinérgico de doenças proliferativas
AU2015203324B2 (en) * 2009-07-20 2016-07-28 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2012027536A1 (en) * 2010-08-26 2012-03-01 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases
CA2874998A1 (en) * 2011-05-27 2012-12-06 Cytocure Llc Methods, compositions, and kits for the treatment of cancer
SG11201402004YA (en) * 2011-11-14 2014-05-29 Cephalon Inc Uracil derivatives as axl and c-met kinase inhibitors
EP3027623A4 (en) * 2013-08-02 2017-03-01 Ignyta, Inc. METHODS OF TREATING VARIOUS CANCERS USING AN AXL/cMET INHIBITOR ALONE OR IN COMBINATION WITH OTHER AGENTS
WO2015116868A2 (en) * 2014-01-29 2015-08-06 Caris Mpi, Inc. Molecular profiling of immune modulators
TWI672141B (zh) * 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子

Similar Documents

Publication Publication Date Title
JP2019527231A5 (https=)
JP2019524851A5 (https=)
CN105849110B (zh) 使用溴结构域和额外终端(bet)蛋白抑制剂的用于癌症的组合疗法
ES2751300T3 (es) Formulación sublingual de riluzol
RU2012151571A (ru) Лекарственные препараты для лечения рака
JP2022533578A5 (https=)
CN103547315A (zh) 用于治疗腺样囊性癌的4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
RU2005128791A (ru) Лекарственные формы, содержащие ag013736
CN115006397A (zh) 一种预防或治疗肿瘤疾病的药物用途
US20090005406A1 (en) Cancer Treatment Method
JP2004510761A5 (https=)
TW202042810A (zh) 一種含cdk4/6抑制劑的組合物與阿那曲唑聯合在製備治療腫瘤疾病的藥物中的用途
CN108472323B (zh) 包含藻蛋白多糖提取物的组合物及其用途
KR102744499B1 (ko) 비인두암을 치료하기 위한 퀴놀린 유도체
Lucendo et al. Esophageal granular cell tumor and eosinophilic esophagitis: two interesting entities identified in the same patient
WO2022123427A1 (en) Methods of identifying a tumor that is sensitive to treatment with talazoparib and methods of treatment thereof
PT1757283E (pt) Potenciador do efeito antitumoral, agente antitumoral e método para a terapia do cancro
Chao-Cheng et al. Lipoblastomatosis combined with intestinal neuronal dysplasia
Zhu African Journal of Pharmaceutical Sciences
CN118019537A (zh) Shp2抑制剂联合egfr-tki治疗和预防肿瘤疾病的医药用途
RU2718048C2 (ru) Противоопухолевое терапевтическое средство
TW202547488A (zh) 於癌症的治療中之化合物Ｉａ和拓樸異構酶Ｉ抑制劑的組合
JP2025533334A5 (https=)
ES2894841T3 (es) Compuestos y composiciones para su uso en el tratamiento de enfermedades mediadas por BCAT1